Form 4: Xenon Pharmaceuticals Executive Acquires Stock Options

Robin Sherrington, EVP of Strategy & Innovation at Xenon Pharmaceuticals, acquired 65,000 stock options on March 11, 2024, according to a Form 4 filing.

Summary

• Robin Sherrington, EVP of Strategy & Innovation at Xenon Pharmaceuticals Inc., acquired 65,000 stock options on March 11, 2024.
• The options have an exercise price of $44.37.
• The options vest 25% on January 1, 2025, and the remaining 75% vest over the following three years in equal monthly installments.
• The options expire on March 10, 2034.
• A Power of Attorney was executed on March 7, 2024, granting Sherry Aulin, Andrea DiFabio, Ilona Lo, and Nathaniel Adams the authority to file SEC documents on Sherrington's behalf.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The acquisition of stock options by an executive could be viewed as a mildly positive signal, suggesting confidence in the company's future.

Positives

• The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and align management's interests with those of shareholders.
• The vesting schedule and exercise price are typical components of stock option agreements, designed to reward long-term value creation.

Stakeholder Impact

• The acquisition of stock options by an executive can potentially impact shareholder value if the executive's performance leads to an increase in the company's stock price.

Key Dates